HC Wainwright & Co. Reiterates Buy on Cullinan Therapeutics, Maintains $28 Price Target
Portfolio Pulse from Benzinga Newsdesk
HC Wainwright & Co. has reiterated its Buy rating on Cullinan Therapeutics (NASDAQ:CGEM) and maintained a price target of $28, indicating confidence in the company's future performance.
September 17, 2024 | 3:10 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
HC Wainwright & Co. has reiterated its Buy rating on Cullinan Therapeutics and maintained a $28 price target, suggesting positive expectations for the company's stock performance.
The reiteration of a Buy rating and maintenance of a $28 price target by HC Wainwright & Co. indicates strong confidence in Cullinan Therapeutics' future performance. This is likely to positively influence investor sentiment and could lead to a short-term increase in the stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100